Oscar Gruss Upgrades Given Imaging Ltd. (GIVN) to Buy
More News related to GIVN
- Given Imaging (GIVN) Announces the Degree of Impact the PillCam SB has on GI Patients, Crohn's Disease
- Three Studies Find PillCam(R) SB Enables Earlier Diagnosis and Treatment of GI Diseases Including Crohn's
- Given Imaging (GIVN) Announces Viability of PillCam Capsule in Pediatric Patients
- Given Imaging Announces RAPID(R) pH Software for Bravo(R) pH Monitoring System
- New Studies Show PillCam(R) SB to Be Clinically Valuable in Classifying and Managing Pediatric GI Symptoms
More News related to Upgrades
- Davenport Upgrades Texas Industries (TXI) to Neutral; Further Estimates Cuts Still Likely
- Citi Upgrades Watson Pharmaceuticals (WPI) to Buy
- Atlantic Equities Upgrades Colgate-Palmolive (CL) to Overweight
- Next Generation Equity Research Upgrades Black Box (BBOX) to Buy
- Capital One Southcoast Upgrades ATP Oil & Gas (ATPG) to Add
Oscar Gruss upgrades Given Imaging Ltd. (Nasdaq: GIVN) from Hold to Buy. Price target increased from $9 to $11.
Oscar analyst says, "The common argument persists that GIVN’s future depends largely on the success of its Colon 2 capsules. We view positive results of trials as an essential milestone in the company’s roadmap and long term growth, as well as a key catalyst for its potential acquisition. We anticipate however, negligible financial contribution from this product in the near term. We believe that GIVN offers a worthy risk/reward opportunity, suited for investors with a long term outlook and no “peptic ulcer”...When focusing on the company's core activity we note that GIVN's sales and distribution channel is secondary only to Olympus (in the US Gastroenterologist market) and we believe that the company, as supported by a wide stations base, can maintain its leverage, thus increasing market share in tandem with improving margins."
To see more analyst ratings on GIVN Click Here.
Given Imaging Ltd. develops, manufactures and markets diagnostic products for the visualization and detection of disorders of the gastrointestinal tract.
Related Categories
UpgradesStocks Mentioned
-0.37Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
